Shanghai S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
24.64
CNY
+0.08%
+8.31%
-4.57%
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 29, 2021 at 03:51 am EDT
Aurisco Pharmaceutical Co.,Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 589.08 million compared to CNY 543.59 million a year ago. Revenue was CNY 589.08 million compared to CNY 543.59 million a year ago. Net income was CNY 133.52 million compared to CNY 140.21 million a year ago. Basic earnings per share from continuing operations was CNY 0.33 compared to CNY 0.39 a year ago. Diluted earnings per share from continuing operations was CNY 0.33 compared to CNY 0.39 a year ago.
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-30
CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2023.
23-09-20
CI
Aurisco Pharmaceutical Co.,Ltd.(XSSC:605116) added to S&P Global BMI Index
23-09-18
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-25
CI
Aurisco Pharmaceutical Gets Auxiton(R) (Dydrogesterone) as First Generic Approval in China
23-06-27
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-28
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-14
CI
Aurisco Cooperates with Cytiva to Build Its First Oligo Flexfactory for Commercial Production
23-01-05
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-30
CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2022.
22-09-20
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-26
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-29
CI
Huayi Boao Quantum Technology Co., Ltd. announced that it has received CNY 100 million in funding from Aurisco Pharmaceutical Co.,Ltd., Gaorong Capital, Sequoia China Investment Management LLP, Turing Ventures, Qiji Chuangtan Investment Management Co., Ltd.
22-04-21
CI
Huayi Quantum announced that it has received CNY 15.5 million in funding from Gaorong Capital, Sequoia China Investment Management LLP, Qiji Chuangtan Investment Management Co., Ltd., Turing Ventures, Aurisco Pharmaceutical Co.,Ltd.
22-04-21
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-29
CI
Certain A Shares of Aurisco Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 21-SEP-2021.
21-09-20
CI
Aurisco Pharmaceutical Co.,Ltd.(SHSE:605116) added to Shanghai Stock Exchange A Share Index
21-09-20
CI
Aurisco Pharmaceutical Co.,Ltd.(SHSE:605116) added to Shanghai Stock Exchange Composite Index
21-09-20
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-30
CI
Aurisco Pharmaceutical Co.,Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021
21-04-28
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
21-04-19
CI
Yangzhou Aurisco Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Aurisco Pharmaceutical Co.,Ltd.
20-10-28
CI
Aurisco Pharmaceutical Co.,Ltd. Announces Major Financial Indicators in 1St Three Quarters of 2020
20-10-27
CI
Aurisco Pharmaceutical Co.,Ltd. has completed an IPO in the amount of CNY 343.17 million.
20-09-10
CI
Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
20-09-09
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Aurisco Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company distributes its products in domestic market and to overseas markets.
More about the company
Last Close Price
24.64
CNY
Average target price
31
CNY
Spread / Average Target
+25.81%
Consensus
1st Jan change
Capi.
-4.57% 1.38B +25.83% 653B +27.00% 556B -6.76% 354B +20.34% 331B +3.00% 296B +13.09% 233B +5.46% 201B -9.61% 193B -6.26% 144B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
AURISCO PHARMACEUTICAL CO.,LTD. 
